Spots Global Cancer Trial Database for central nervous system neoplasms
Every month we try and update this database with for central nervous system neoplasms cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer | NCT05386108 | Breast Neoplasm... Brain Neoplasms Neoplasms by Si... Neoplasms Breast Diseases Central Nervous... Brain Diseases Central Nervous... | Elacestrant Abemaciclib | 18 Years - | Stemline Therapeutics, Inc. | |
| Biomarker Analysis of Central Nervous System Tumors | NCT02692898 | Central Nervous... Primary Brain N... Neoplasms, Brai... Cancer of the B... Brain Cancer | - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| Retrospective Study of MRI With MULTIHANCE at 0.10 and 0.05 mmol/Kg Dose in CNS Patients | NCT03147989 | Central Nervous... Central Nervous... | MultiHance | 2 Years - | Bracco Diagnostics, Inc | |
| Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma | NCT01582152 | Brain Neoplasms Central Nervous... | TPI287 Bevacizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Biomarker Analysis of Central Nervous System Tumors | NCT02692898 | Central Nervous... Primary Brain N... Neoplasms, Brai... Cancer of the B... Brain Cancer | - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement | NCT04543188 | Malignant Melan... Carcinoma, Non-... Brain Neoplasms... Brain Neoplasms Malignant Neopl... | PF-07284890 Binimetinib Midazolam | 16 Years - | Pfizer | |
| Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer | NCT05386108 | Breast Neoplasm... Brain Neoplasms Neoplasms by Si... Neoplasms Breast Diseases Central Nervous... Brain Diseases Central Nervous... | Elacestrant Abemaciclib | 18 Years - | Stemline Therapeutics, Inc. | |
| Diagnostic Assessment of 18F-fluciclovine and 18F-FDG -PET/MRI of Primary Central Nervous System Lymphoma | NCT03188354 | Lymphoma, Non-H... Central Nervous... | 18F-FDG 18F-fluciclovin... standard MRI | 18 Years - | Norwegian University of Science and Technology | |
| Retrospective Study of MRI With MULTIHANCE at 0.10 and 0.05 mmol/Kg Dose in CNS Patients | NCT03147989 | Central Nervous... Central Nervous... | MultiHance | 2 Years - | Bracco Diagnostics, Inc | |
| Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma | NCT01290692 | Grade IV Glioma Grade IV Astroc... Glioblastoma Mu... | TVI-Brain-1 | 18 Years - | TVAX Biomedical | |
| Pediatric Prospective Personalized Immune and Target Identification Trial | NCT04859543 | Central Nervous... Pediatric Cance... GEN1 Gene Mutat... Tumor, Brain | FoundationOneHe... | 1 Year - 19 Years | Masaryk University | |
| Pediatric Prospective Personalized Immune and Target Identification Trial | NCT04859543 | Central Nervous... Pediatric Cance... GEN1 Gene Mutat... Tumor, Brain | FoundationOneHe... | 1 Year - 19 Years | Masaryk University | |
| Combined O-(2-[18F]Fluoroethyl)-L-tyrosine (FET) Positron Emission Tomography (PET) and Simultaneous Magnetic Resonance Imaging (MRI) Follow-up in Re-irradiated Recurrent Glioblastoma Patients | NCT01579253 | Glioblastoma Nervous System ... Central Nervous... Astrocytoma Glioma Neoplasms, Neur... Neuroectodermal... Neoplasms by Hi... Neoplasms, Nerv... | 18 Years - 75 Years | Ludwig-Maximilians - University of Munich | ||
| Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | NCT04541082 | Central Nervous... Glioblastoma Gliosarcoma, Ad... Anaplastic Olig... Anaplastic Astr... Pilocytic Astro... Oligodendroglio... Gliomatosis Cer... Pleomorphic Xan... Anaplastic Pleo... Diffuse Midline... Ependymoma Ependymoma, Ana... Medulloblastoma Teratoid Rhabdo... Neuroectodermal... Neuroectodermal... Anaplastic Meni... Atypical Mening... Choroid Plexus ... Pineal Tumor Diffuse Astrocy... Glial Tumor | ONC206 | 18 Years - | Chimerix | |
| Retrospective Study of MRI With MULTIHANCE at 0.10 and 0.05 mmol/Kg Dose in CNS Patients | NCT03147989 | Central Nervous... Central Nervous... | MultiHance | 2 Years - | Bracco Diagnostics, Inc | |
| 5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas | NCT05850377 | High Grade Glio... Glioma Glioma, Maligna... Neoplasms, Neur... Neuroectodermal... Photosensitizin... Neoplasm Malign... Brain Neoplasms... Central Nervous... Brain Tumor Tumour, Residua... | 5-Aminolevulini... Fluorescence-Gu... | 18 Years - 75 Years | Sociedad de Lucha Contra el Cáncer del Ecuador | |
| Retrospective Study of MRI in Pediatric Patients | NCT02291822 | Central Nervous... Central Nervous... | Gadobenate Dime... | - 2 Years | Bracco Diagnostics, Inc | |
| DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors | NCT02197169 | Glioblastoma or... | Single intratum... Interferon-gamm... | 18 Years - | DNAtrix, Inc. | |
| A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients | NCT00329589 | Brain Cancer Head and Neck C... Cervix Cancer Central Nervous... | Velcade (bortez... | 18 Years - | Thomas Jefferson University | |
| Comparison of Contrast Agents for MRI Perfusion Analysis in Brain Tumor Patients | NCT02095353 | Central Nervous... | 19 Years - | University of Nebraska | ||
| Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients | NCT04657315 | Glioblastoma Adult Gliosarco... Neoplasms, Brai... Neoplasms, Germ... Recurrent Gliob... | MSC11FCD | 19 Years - 70 Years | CHA University | |
| Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab | NCT01931098 | Glioblastoma Glioblastoma Mu... Gliosarcoma Brain Neoplasms Central Nervous... | topotecan pazopanib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrs | NCT03750188 | Central Nervous... Central Nervous... | ProHance | 1 Day - 2 Years | Bracco Diagnostics, Inc | |
| Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis | NCT00185848 | Brain Cancer Arthritis, Rheu... Central Nervous... Glioma | [18F]FHBG | 18 Years - | Stanford University | |
| Coproporphyrine Isomers and Methotrexate Elimination | NCT00822432 | Central Nervous... Lymphoma, Large... Precursor B-Cel... Burkitt Lymphom... | 18 Years - | Assistance Publique - Hôpitaux de Paris | ||
| Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients | NCT04657315 | Glioblastoma Adult Gliosarco... Neoplasms, Brai... Neoplasms, Germ... Recurrent Gliob... | MSC11FCD | 19 Years - 70 Years | CHA University | |
| Diagnostic Efficiency of Artificial Intelligence for Surgical Neuropathology | NCT04671368 | Central Nervous... | Artificial Inte... Practicing Path... Gold Standard | 18 Years - | Huashan Hospital | |
| Retrospective Study of MRI in Pediatric Patients | NCT02291822 | Central Nervous... Central Nervous... | Gadobenate Dime... | - 2 Years | Bracco Diagnostics, Inc | |
| A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma | NCT05664243 | Glioblastoma | Autologous gene... Allogeneic gene... | 18 Years - | In8bio Inc. | |
| Retrospective Study of MRI in Pediatric Patients | NCT02291822 | Central Nervous... Central Nervous... | Gadobenate Dime... | - 2 Years | Bracco Diagnostics, Inc | |
| Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy | NCT00629187 | Central Nervous... Neoplasm Metast... | Temozolomide | 18 Years - 70 Years | Tufts Medical Center | |
| A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma | NCT05664243 | Glioblastoma | Autologous gene... Allogeneic gene... | 18 Years - | In8bio Inc. | |
| A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients | NCT00329589 | Brain Cancer Head and Neck C... Cervix Cancer Central Nervous... | Velcade (bortez... | 18 Years - | Thomas Jefferson University | |
| Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma | NCT01290692 | Grade IV Glioma Grade IV Astroc... Glioblastoma Mu... | TVI-Brain-1 | 18 Years - | TVAX Biomedical | |
| Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma | NCT01081223 | Glioma High Grade Astr... Glioblastoma Mu... | Cancer vaccine ... | 18 Years - | TVAX Biomedical | |
| Diagnostic Assessment of 18F-fluciclovine and 18F-FDG -PET/MRI of Primary Central Nervous System Lymphoma | NCT03188354 | Lymphoma, Non-H... Central Nervous... | 18F-FDG 18F-fluciclovin... standard MRI | 18 Years - | Norwegian University of Science and Technology | |
| A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors | NCT03257631 | Central Nervous... Medulloblastoma | Pomalidomide Pomalidomide | 1 Year - 21 Years | Celgene |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
